Shots:

• The P-I single/multiple-ascending dose clinical trial evaluates the safety, tolerability, PK & PD of ABX-002 in healthy volunteers. Following multiple-ascending study completion, Autobahn plans to initiate a P-Ib patient cohort to evaluate the safety & potential effects of ABX-002 in patients with MDD
• Previously, the pre-clinical data evaluating ABX-002 had depicted a target engagement of ABX-002 in brain regions linked with depression along with a reduction in peripheral liabilities vs synthetic thyroid hormone (T3)
• ABX-002 is a potent & selective, brain-boosting TRβ agonist that is being evaluated by Autobahn as a potential adjunctive treatment

Ref: Businesswire | Image: Autobahn